The prevalence of atrial fibrillation (AF) is increasing as the population ages. AF treatment-
related complications also increase markedly in older adults (defined as≥ 75 years of age …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

In the past six decades, heparin and warfarin were the primary anticoagulants prescribed for
treatment and prophylaxis of venous thromboembolism worldwide. This has been …

Abstract Purpose Base de Datos para la Investigación Farmacoepidemiológica en Atención
Primaria (BIFAP) is a population based database administered by the AEMPS (Spanish …

Older adults, the fastest growing population, represent almost 50% of all users of direct oral
anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …

Background. Data directly comparing trends in the use of different oral anticoagulants
(OACs) among patients with atrial fibrillation (AF) from different countries are limited. We …

BACKGROUND: Direct oral anticoagulants (DOACs) are widely used for the prevention of
stroke in nonvalvular atrial fibrillation (NVAF); however, real-world primary nonadherence …

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia associated with an
increased risk of stroke and thromboembolism. Anticoagulation with Vitamin K antagonists …

Introduction Per-label dosing of direct oral anticoagulants (DOACs) is important for the
prevention of stroke and systemic embolism among patients with non-valvular atrial …